 Oragenics, Inc. NYSE American: OGEN, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis OM, today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy to use oral rinsing system designed to prevent and treat OM. The ongoing Phase 2 trial is a double-blind, placebo-controlled, two-arm, multi-country, multi-center trial, in which 200 patients have been randomized in a 1:1 ratio to receive either AG013 dapatifagene navolactibac or a placebo. The purpose of the study NCT03234465 is to evaluate the safety, tolerability and efficacy of topically administered AG013 compared to placebo for reducing the incidence and severity of OM in patients undergoing traditional chemoradiation CRT for the treatment of head and neck cancer HNC. 